The Half Moon Transcatheter Mitral Valve Repair (TMVr) Pilot Study
Study Details
Study Description
Brief Summary
The study is a prospective, multi-center, single-arm, non-randomized, Early Feasibility Study (EFS) to evaluate the safety and performance of the Half Moon TMVr System in patients with severe, symptomatic mitral regurgitation, who are at high risk for conventional mitral valve surgery.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Half Moon TMVr System The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve. |
Device: Half Moon TMVr System
The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
|
Outcome Measures
Primary Outcome Measures
- Adverse Events [30 Days]
Evaluation of the nature, severity and frequency of complications associated with the delivery and/or implantation of the device
Secondary Outcome Measures
- Device Placement [30 Days (+ annually through 5 years)]
Assessment of the ability to accurately deliver and place the implant within the native anatomy
- Device Performance [30 Days (+ annually through 5 years)]
The degree of improvement of MR grade
- Symptom Improvement [30 Days (+ annually through 5 years)]
The degree of improvement of MR symptoms
- Device Durability [30 Days (+ annually through 5 years)]
The durability of TMVr function
Eligibility Criteria
Criteria
Key Inclusion Criteria:
-
Moderately severe or severe mitral regurgitation (MR Grade ≥ 3+)
-
Symptomatic mitral regurgitation (NYHA Class II-IV), despite guideline-directed medical therapy (GDMT) determined by the local multidisciplinary heart team
-
Deemed, by the local multidisciplinary heart team, to be at high risk for mitral valve surgery and not appropriate for commercially approved transcatheter mitral valve therapies
-
Age ≥ 21
-
Native mitral valve geometry and size compatible with the Half Moon TMVr implant
-
Anatomy suitable for transfemoral transseptal access with the Half Moon TMVr System
-
Willing to sign Informed Consent for participation in the study and return for all required post-procedure follow-up visits
Key Exclusion Criteria:
-
Prior transseptal intervention with occlusion device currently implanted
-
Implanted with venous stents (iliac and femoral) including inferior vena cava (IVC) filter or congenital abnormalities of the IVC that would preclude ability for transfemoral access with the delivery system
-
Evidence of intracardiac, inferior vena cava, or femoral venous mass, thrombus, or vegetation
-
Prohibitive mitral annular or leaflet calcification
-
Diseased mitral anterior leaflet such as flail or prolapse
-
Left ventricular ejection fraction (LVEF) < 25%, or LVEF 25-30% in the presence of left ventricular end diastolic volume index (LVEDVi) >120mL/m2 as measured by resting echocardiogram within 30 days of the Index Procedure
-
Left ventricular end diastolic diameter (LVEDD) > 75mm
-
Pulmonary hypertension with resting pulmonary artery systolic pressures ≥ 2/3 systemic systolic pressure
-
Right-sided congestive heart failure with echocardiographic evidence of severe right ventricular dysfunction
-
Severe tricuspid regurgitation
-
Prior mitral valve surgery or endovascular procedure, or need for other valve surgery/procedure
-
Any endovascular therapeutic interventional or surgical procedure performed within 30 days prior to enrollment
-
Prior stroke, TIA, or myocardial infarction within 90 days
-
Need for coronary revascularization
-
Severe symptomatic carotid artery stenosis
-
Severe Chronic Obstructive Pulmonary Disease (COPD) demonstrated by Forced Expiratory Volume (FEV1) < 750cc
-
Need for emergent surgery
-
Endocarditis within 6 months
-
Subject is unwilling or unable to adhere to the protocol recommended anticoagulation treatment
-
GI bleeding within 6 months
-
History of bleeding diathesis or coagulopathy or patient will refuse blood transfusion
-
Hemodynamic instability requiring dependency on either inotropic agents or mechanical circulatory support
-
Platelet count of <75,000 cells/mm3
-
Renal insufficiency (Creatinine > 2.5 mg/dL)
-
Active infections requiring current antibiotic therapy (if temporary illness, patients may enroll 2 weeks after discontinuation of antibiotics)
-
Contraindication to transesophageal echocardiography (TEE)
-
Known hypersensitivity or contraindication to study or procedure medications/contrast which cannot be adequately managed medically
-
Pregnant, nursing or planning to be pregnant. (Female participants of childbearing potential must have a negative pregnancy test prior to enrollment)
-
Currently participating in an investigational drug or another device study that has not yet reached its primary endpoint
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Columbia University Medical Center/NewYork Presbyterian Hospital | New York | New York | United States | 10032 |
Sponsors and Collaborators
- Half Moon Medical
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CIP-0001